Last reviewed · How we verify
Chlorthalidone with potassium chloride — Competitive Intelligence Brief
marketed
Thiazide-like diuretic with potassium supplement
Sodium-chloride cotransporter (NCC)
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Chlorthalidone with potassium chloride (Chlorthalidone with potassium chloride) — Brigham and Women's Hospital. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, while potassium chloride supplementation replaces electrolytes lost during diuresis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Chlorthalidone with potassium chloride TARGET | Chlorthalidone with potassium chloride | Brigham and Women's Hospital | marketed | Thiazide-like diuretic with potassium supplement | Sodium-chloride cotransporter (NCC) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Thiazide-like diuretic with potassium supplement class)
- Brigham and Women's Hospital · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Chlorthalidone with potassium chloride CI watch — RSS
- Chlorthalidone with potassium chloride CI watch — Atom
- Chlorthalidone with potassium chloride CI watch — JSON
- Chlorthalidone with potassium chloride alone — RSS
- Whole Thiazide-like diuretic with potassium supplement class — RSS
Cite this brief
Drug Landscape (2026). Chlorthalidone with potassium chloride — Competitive Intelligence Brief. https://druglandscape.com/ci/chlorthalidone-with-potassium-chloride. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab